Banked research specimens reported as available through Spectrum Clinical Research Labs' partner network. Select a category to request a quote.
How to read this list
Categories reflect partner reports dated September 29 – November 5, 2026, reviewed November 5, 2026. Exact quantities, weights, donor eligibility, QC, and availability are confirmed during quotation — listings are not guaranteed counts or Spectrum-held stock. For research use only.
11 of 11 categories shown
INV-001 · Lung oncology
Lung adenocarcinoma
Partner-reported
Banked frozen lung adenocarcinoma tissue reported with aliquot weights approximately 0.012–1.031 g across reviewed reports; some aliquot weights require confirmation. Selected OCT-embedded material also reported. The October 14, 2026 report contributes 18 distinct frozen lung adenocarcinoma cases with reported specimen weights 0.080–0.331 g. Unique-donor quantities and final availability are subject to confirmation at quotation.
Banked frozen lung squamous-cell carcinoma tissue reported with aliquot weights approximately 0.013–0.793 g across reviewed reports; some aliquot weights require confirmation. Selected OCT-embedded material also reported. The October 14, 2026 report contributes 18 distinct frozen lung squamous-cell carcinoma cases with reported specimen weights 0.137–0.331 g. Unique-donor quantities and final availability are subject to confirmation at quotation. An October 22, 2026 verification confirms selected U.S.-collected treatment-naive frozen NSCLC material with squamous/large-cell features, reported weights 0.355–0.400 g, currently available and reservable for up to two weeks; ships on dry ice; clinical/pathology data and ethics documentation reported available. Final availability remains subject to confirmation at quotation.
Banked frozen large-cell lung carcinoma tissue reported with aliquot weights approximately 0.060–0.488 g across reviewed reports; some aliquot weights require confirmation. The October 14, 2026 report contributes 4 distinct frozen large/solid-cell lung carcinoma cases with reported specimen weights 0.154–0.481 g. Fresh prospective tissue remains a separate need and is not confirmed by this inventory. Final availability is subject to confirmation at quotation. An October 22, 2026 verification confirms selected U.S.-collected treatment-naive frozen large-cell NSCLC material with basaloid, neuroendocrine, and squamous features, reported weights 0.222–0.243 g, currently available and reservable for up to two weeks; ships on dry ice; clinical/pathology data and ethics documentation reported available. Final availability remains subject to confirmation at quotation.
Banked snap-frozen small-cell lung carcinoma (SCLC) tissue reported as in stock by a partner on October 8, 2026. Weights, quantities, and final availability are subject to confirmation at quotation.
Fresh-frozen normal/adjacent tissue across brain, lung, heart, kidney, intestine, stomach, pancreas, spleen, skeletal muscle, colon, and liver. Selected OCT formats reported for brain, liver, lung, heart, kidney, stomach, and spleen. Normal/adjacent tissue may come from disease donors and is not equivalent to healthy-donor tissue.
Broad banked oncology category in fresh-frozen and FFPE formats, with selected matched plasma/buffy coat where reported. Specific indications require confirmation before quotation.
120 healthy/normal-control frozen remnant CSF samples were confirmed by one partner on October 5, 2026. An additional partner inventory reviewed October 7 lists normal CSF in 1 mL aliquots with negative HIV, HBV, HCV, and VDRL screening. Additional quantities and final availability are subject to confirmation at quotation.
An October 22, 2026 verification confirms one currently available, treatment-naive DLBCL matched set with a lymph-node FFPE block, 22 mL total plasma, and 2 mL total buffy coat from the same donor and pre-treatment collection. The set may be reserved for up to two weeks; partner-reported ethical approvals are in place and estimated lead time is 2–3 weeks after project award. Exact FFPE block dimensions and ability to provide 12 × 10 µm sections with at least 10% tumor remain unconfirmed, so fulfillment of the active DLBCL request is not yet established. Final availability is subject to confirmation at quotation.
An October 14, 2026 report lists 50 distinct U.S.-collected benign-disease tissue cases with reported specimen weights 0.110–0.450 g across pancreas, liver, small intestine, stomach, common bile duct, abdominal cavity, and breast. These are disease-derived controls, not healthy-normal tissue. All availability is subject to confirmation at quotation.
An October 20, 2026 inventory report lists banked FFPE cartilage with osteoarthritis and other degenerative findings, normal/normal-adjacent cartilage, and selected joint tissue and normal synovium. Normal/adjacent tissue may come from disease donors and is not equivalent to healthy-donor tissue. Anti-TNF response groups, longitudinal pairing, and RNA quality for spatial transcriptomics are not established. Specimen quantities and final availability require confirmation at quotation. On October 22, one adult U.S. normal-synovium FFPE block was confirmed and reserved, with an estimated yield of approximately 50–75 sections at 5 µm. Pathology, ethics, and consent documentation were reported available through the private inventory file. RIN is not available for this FFPE material, and spatial-transcriptomics suitability has not been established. Remaining treatment-response cohorts and a second control require prospective sourcing and feasibility review. Final availability remains subject to confirmation at quotation.
Two partner inventory reports reviewed October 29, 2026 report banked frozen remnant CSF spanning adult and pediatric cases. One report separates epilepsy from non-epilepsy clinical indications and includes de-identified diagnosis/laboratory metadata; the other provides age, sex, collection date, volume, and reported 0–1 freeze/thaw cycles but lacks diagnosis detail. Reported aliquot volumes across the reports are approximately 0.9–2.5 mL, with some values expressed only as greater-than thresholds. These are clinical remnant samples, not healthy controls, and not every reported sample is necessarily currently available. Matched blood is unavailable. A late partner report received November 5, 2026 lists three multiple-myeloma CSF samples with reported aliquot volumes of 1.2–3 mL; clinical comorbidities and quality notes are documented in the private source, and exact eligibility and current availability remain subject to confirmation at quotation. Final eligibility, quantity, and availability are subject to confirmation at quotation.